A synthetic TGFB2 mRNA-targeting anti-sense phosphorothioate oligodeoxynucleotide (S-ODN) exhibited promising single-agent clinical activity associated with durable complete and partial responses in adult patients with recurrent or refractory glioblastoma and anaplastic astrocytoma when administered intratumorally via CED [37,38]. The gene discussed is TGFB2; the disease is anaplastic astrocytoma.